Literature DB >> 24833082

Impact of preexisting diabetes mellitus on transplantation outcomes in hematopoietic stem cell transplantation.

Mania Radfar1, Toktam Faghihi, Molouk Hadjibabaie, Faeze Ebrahimi, Mostafa Qorbani, Masoud Iravani, Ardeshir Ghavamzadeh.   

Abstract

New onset diabetes mellitus is frequently observed following hematopoietic stem cell transplantation (HSCT) and is associated with adverse transplantation outcomes. However, the outcomes of patients with preexisting diabetes mellitus undergoing HSCT are largely unknown. We aimed to explore the impact of preexisting diabetes on transplantation outcomes in HSCT. In a retrospective study, medical charts of 34 HSCT recipients with diabetes mellitus undergoing allogeneic or autologous transplantation were reviewed and compared with 71 HSCT recipients without diabetes. Primary outcome was overall survival. Secondary outcomes included hematopoietic recovery, length of hospital stay, febrile neutropenia, acute and chronic graft-versus-host disease (GVHD), primary disease recurrence, and non-relapse mortality (NRM). On univariate analysis, there was no difference in transplantation outcomes in recipients with diabetes compared with recipients without diabetes. However, after adjusting for potential covariates, multivariate analysis demonstrated that having diabetes before HSCT significantly predicted outcome and decreased overall survival (hazard ratio 0.51, 95% confidence interval: 0.27-0.97, p value: 0.04). This study suggests that patients with diabetes mellitus undergoing allogeneic or autologous HSCT may have inferior survival rates and warrant further attention.

Entities:  

Keywords:  Febrile neutropenia; Pre-transplant fasting plasma glucose; neutrophil engraftment; overall survival; platelet engraftment; post-transplantation hyperglycemia

Mesh:

Year:  2014        PMID: 24833082     DOI: 10.3109/07435800.2014.914037

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  5 in total

1.  Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients.

Authors:  Jenna Sopfe; Laura Pyle; Amy K Keating; Kristen Campbell; Arthur K Liu; R Paul Wadwa; Michael R Verneris; Roger H Giller; Gregory P Forlenza
Journal:  Blood Adv       Date:  2019-02-12

Review 2.  How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.

Authors:  S Fuji; A Rovó; K Ohashi; M Griffith; H Einsele; M Kapp; M Mohty; N S Majhail; B G Engelhardt; A Tichelli; B N Savani
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

3.  Incidence and risk factors for ocular GVHD after allogeneic hematopoietic stem cell transplantation.

Authors:  K-S Na; Y-S Yoo; J W Mok; J W Lee; C-K Joo
Journal:  Bone Marrow Transplant       Date:  2015-08-24       Impact factor: 5.483

4.  c-D-index at day 11 can predict febrile neutropenia during chemotherapy in acute myeloid leukemia.

Authors:  Hiroyuki Kubo; Osamu Imataki; Yukiko Hamasaki Kubo; Makiko Uemura
Journal:  PLoS One       Date:  2022-03-17       Impact factor: 3.240

5.  Nutritional status and hyperglycemia in the peritransplant period: a review of associations with parenteral nutrition and clinical outcomes.

Authors:  Marina Verdi Schumacher; Gustavo Adolpho Moreira Faulhaber
Journal:  Rev Bras Hematol Hemoter       Date:  2017-02-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.